US FDA panel votes against expanded use of Amarin drug

US FDA panel votes against expanded use of Amarin drug

The FDA suggested that approval should be withheld pending the results of an 8,000-patient trial being conducted by Amarin that is expected to shed light on whether Vascepa actually cuts cardiovascular risk. Results of the trial are expected in late 2016.

6
Like
Save

Comments

Write a comment

*